• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Gralise (gabapentin)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Gralise (gabapentin)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Gralise is an extended release formulation of the approved drug gabapentin, developed on DepoMed's Gastric Retention technology. Gabapentin is a gamma-aminobutyric acid (GABA), analogue. The mechanism of action by which gabapentin exerts its analgesic action is unknown but in animal models of analgesia, gabapentin prevents allodynia (pain-related behavior in response to a normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli).

    Gralise is specifically indicated for the management of postherpetic neuralgia.

    Gralise is supplied as a tablet for oral administration. Gralise should be tirated to an 1800 mg dose taken orally once daily with the evening meal. The recommended titration schedule is Day 1: 300mg; Day 2: 600mg; Days 3-6: 900mg; Days 7-10: 1200mg; Days 11-14: 1500mg and Day 15: 1800mg.

    Clinical Results

    FDA Approval
    The FDA approval of Gralise was based on a double-blind, placebo-controlled, multicenter study. This study enrolled 452 subjects between the age of 21 to 89 with postherpetic neuralgia persisting for at least 6 months and compared Gralise 1800 mg once daily with placebo for 11 weeks. Double-blind treatment began with titration starting at 300 mg/day and titrated up to a total daily dose of 1800 mg over 2 weeks, followed by 8 weeks fixed dosing at 1800 mg once daily, and then 1 week of dose tapering. During the 8-week stable dosing period, patients took 3 active or placebo tablets each night with the evening meal. During baseline and treatment, patients recorded their pain in a daily diary using an 11-point numeric pain rating scale. The mean baseline pain score was 6.6 and 6.5 for Gralise and placebo-treated patients, respectively. Treatment with Gralise statistically significantly improved the endpoint mean pain score from baseline.

    Side Effects

    Adverse events associated with the use of Gralise may include, but are not limited to, the following:

    • dizziness
    • somnolence
    • headache
    • peripheral edema
    • diarrhea

    Mechanism of Action

    Gralise is an extended release formulation of the approved drug gabapentin, developed on DepoMed's Gastric Retention technology. Gabapentin is a gamma-aminobutyric acid (GABA), analogue. The mechanism of action by which gabapentin exerts its analgesic action is unknown but in animal models of analgesia, gabapentin prevents allodynia (pain-related behavior in response to a normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli).

    Literature References

    Wallace MS, Irving G, Cowles VE Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clinical Drug Investigation 2010;30(11):765-76

    Irving G, Jensen M, Cramer M, Wu J, Chiang YK, Tark M, Wallace M Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. The Clinical Journal of Pain 2009 Mar-Apr;25(3):185-92

    Additional Information

    For additional information regarding Gralise or postherpetic neuralgia, please visit the Depomed web page.

    Approval Date: 2011-02-01
    Company Name: Abbott Laboratories
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing